U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096843) titled 'A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy' on July 24.
Brief Summary: To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Primary Membranous Nephropathy
Intervention:
DRUG: budoprutug
Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Climb Bio, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....